Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected

Silexion Therapeutics Corp

CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.
Regulatory submissions planned for Q4 2025 (Israel) and Q1 2026 (EU).
Phase 2/3 clinical trials for SIL204 expected to commence in first half of 2026.
SIL204 previously showed up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.